Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 7, 2014, Pages 605-616

  Wen, X J ^a   Wang, L M ^b   Liu, Z L ^a   Huang, A ^a   Liu, Y Y ^a   Hu, J Y ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Adjunctive therapy; Atypical antipsychotics; Major depressive disorder; Meta analysis

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; DSM-IV; HUMAN; INFORMATION PROCESSING; MAJOR DEPRESSION; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT CODING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHEMOTHERAPY, ADJUVANT; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; HUMANS; MIDDLE AGED; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RISPERIDONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903760754     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143672     Document Type: Article

References (38)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602, doi: 10.1001/archpsyc.62.6.593.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504, doi: 10.1016/S0140-6736(96)07492-2.
3. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43, doi: 10.3109/15622970209150599.
4. Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 2001; 46 (Suppl 1): 21S-28S.
5. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157: 1501-1504, doi: 10.1176/appi. ajp.157.9.1501.
6. Nemeroff CB. Prevalence and management of treatmentresistant depression. J Clin Psychiatry 2007; 68 (Suppl 8): 17-25.
7. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998; 59: 608-619, doi: 10.4088/JCP.v59n1108.
8. Raskin A, Schulterbrandt JG, Reatig N, McKeon JJ. Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry 1970; 23: 164-173, doi: 10.1001/archpsyc.1970.01750020068009.
9. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256-259, doi: 10.4088/JCP.v60n0410.
10. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a metaanalysis. J Clin Psychiatry 2007; 68: 826-831, doi: 10.4088/ JCP.v68n0602.
11. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-991, doi: 10.1176/appi.ajp.2009.09030312.
12. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
13. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81: 87-97, doi: 10.1159/000332050.
14. Lin CH, Lin SH, Jang FL. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J Clin Psychopharmacol 2011; 31: 563-568, doi: 10.1097/JCP.0b013e31822bb0db.
15. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296, doi: 10.1111/j.2044-8260.1967.tb00530.x.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389, doi: 10.1192/bjp.134.4.382.
17. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008; 117: 412-419, doi: 10.1111/j.1600-0447.2008.01194.x.
18. Jaeschke R, Guyatt G, Shannon H, Walter S, Cook D, Heddle N. Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association. CMAJ 1995; 152: 351-357.
19. Citrome L. Show me the evidence: using number needed to treat. South Med J 2007; 100: 881-884, doi: 10.1097/SMJ. 0b013e3180f63246.
20. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70: 540-549, doi: 10.4088/ JCP.08m04629.
21. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007; 68: 843-853, doi: 10.4088/JCP.v68n0604.
22. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13: 917-932, doi: 10.1017/S1461145710000015.
23. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43: 205-214, doi: 10.1016/j.jpsychires.2008.05.003.
24. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, et al. Risperidone for treatmentrefractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147: 593-602, doi: 10.7326/0003-4819-147-9-200711060-00003.
25. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychopharmacol 2008; 28: 156-165, doi: 10.1097/JCP.0b013e31816774f9.
26. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebocontrolled pilot study. Depress Anxiety 2007; 24: 487-494, doi: 10.1002/da.20275.
27. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134, doi: 10.1176/appi.ajp.158.1.131.
28. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66: 1289-1297, doi: 10.4088/JCP.v66n1012.
29. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68: 224-236, doi: 10.4088/JCP.v68n0207.
30. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23: 364-372, doi: 10.1002/da.20130.
31. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69: 1228-1336, doi: 10.4088/JCP. v69n0805.
32. Khullar A, Chokka P, Fullerton D, McKenna S, Blackman A. Quetiapine as treatment of non-psychotic unipolar depression with residual symptoms: double blind, randomized, placebo controlled study. American Psychiatric Association Annual Meeting, Toronto, Canada. 2006.
33. Mattingly G, Ilivicky H, Canale J, Anderson R. Quetiapine combination for treatment-resistant depression. American Psychiatric Association 2006 Annual Meeting: New Research Abstracts. 2006; May: 20-25, Toronto; 2006.
34. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010; 122: 39-48, doi: 10.3810/pgm.2010.07.2174.
35. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39, doi: 10.1016/S0024-3205 (00)00911-5.
36. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011; 25: 109-127, doi: 10.2165/11538980-000000000-00000.
37. Trivedi MH, Rush AJ, Pan JY, Carmody TJ. Which depressed patients respond to nefazodone and when? J Clin Psychiatry 2001; 62: 158-163, doi: 10.4088/JCP. v62n0304.
38. Molnar FJ, Hutton B, Fergusson D. Does analysis using "last observation carried forward" introduce bias in dementia research? CMAJ 2008; 179: 751-753, doi: 10.1503/ cmaj.080820.